Study Graphic

The Pfizer New Haven Clinical Research Unit is conducting a study of a marketed prescription drug. It was approved by the United States Food and Drug Administration (FDA) to treat people with mild to moderate atopic dermatitis (AD). AD is a form of eczema (itchy, inflamed skin rash). It has been on the market since 2016. It is a topical (applied to the skin) ointment that is applied directly to the affected area(s) of the skin.

Study Number: C3291042

You may be eligible if:

  • You are a healthy male or female 18-55 years of age.
  • You are able to meet all eligibility criteria.
  • You are able to comply with all study visits.

You will be compensated up to $350.00 for travel expenses to and from screening

You will be compensated $1875.00 for completion of the study

This study involves:

You will be in this study up to about 38 days. This does not include the time between screening and dosing, which can be up to 28 days.

This study involves:

  • 1 dosing period
  • 5 overnight stays
  • 1 follow-up phone call (31 to 37 days after the start of dosing)

Please review the Informed Consent Document: C3291042 revised ICD v14Nov2018

Please review more information about the study: C3291042 final Guidelines Restriction Dates v19Oct2018_G1